What is the Guidelines Challenge?

Rani Lill Anjum

CauseHealth recently organised a conference in Oxford called The Guidelines Challenge: Philosophy, Practice, Policy.

For those who missed the event, podcasts of the talks are available on our YouTube channel, and there is also a summary from each of the two days on Storify (day 1, day 2). There is also a Twitter hashtag, #GuidelinesChallenge.
(more…)

Advertisements

Philosophy of Pharmacology Symposium at ECAP9 (LMU Munich, Aug 2017)

WP_20170822_16_24_14_Pro_LIPart of the CauseHealth team went to ECAP9 and spoke about why deep understanding of causation, mechanisms and the local context is essential for drug safety. We were also excited to be in a session with Ralph Edwards, former Director of the Uppsala Monitoring Centre for drug safety, which acts as the official advisor for the World Health Organisation (WHO). Thanks for having us, Barbara!

Philosophy of Pharmacology

The symposium “Philosophy of Pharmacology: Theoretical Foundations, Methodological Evolution, and Public Health Policy” took place at LMU Munich on 22 August, 2017, as part of the Ninth Congress of Analytic Philosophy  (ECAP9) of the European Society of Analytic Philosophy (ESAP). The congress was jointly organized by Barbara Osimani, Jürgen Landes, and Roland Poellinger. The program featured contributions by four speakers:

  1. Barbara Osimani (Ancona / LMU)
  2. Rani Lill Anjum (Norwegian University)
  3. Elena Rocca (Norwegian University)
  4. Ralph Edwards (Uppsala Monitoring Centre of the World Health Organization)

At the overlap of philosophy and health science, this symposium offered a panorama of the complex network of interests found in pharmacology (financial, reputational etc.) as well as the scientific and social ecosystem in which pharmacology is embedded. A special focus was on current debates regarding 1) standards for evidence evaluation, 2) methodological evolution, and 3) pragmatics as well as epistemic asymmetry of causal assessment of risk…

View original post 519 more words

New CauseHealth paper about risk assessment of genetically modified plants

by Elena Rocca

One idea promoted by CauseHealth is that, when evaluating evidence, pre-existing theoretical frameworks count as much as the data. For instance, data from a certain trial assume a particular significance depending on the general background theoretical understanding we have when we interpret them. In this new CauseHealth article, Elena Rocca and Fredrik Andersen show that, when evaluating health risks related to the use of genetically modified plants in agriculture, different ontological starting points play an essential role for the final risk evaluation. (more…)

What does CauseHealth mean by N=1?

by Roger Kerry

N=1” is a slogan used to publicise a core purpose of the CauseHealth project. N=1 refers to a project which is focussed on understanding causally important variables which may exist at an individual level, but which are not necessarily represented or understood through scientific inquiry at a population level. There is an assumption that causal variables are essentially context-sensitive, and as such although population data may by symptomatic of causal association, they do not constitute causation. The project seeks to develop existing scientific methods to try and better understand individual variations. In this sense, N=1 has nothing at all to do with acquiescing to “what the patient wants”, or any other similar fabricated straw-man characterisations of the notion which might emerge during discussions about this notion. (more…)

The Patient: The Beginning of it All

By Elena Rocca

We often think of the perfect medical research and health care system as a system that puts patient’s care as the final aim of a long process. In a way, this is hardly controversial: patient’s interest must be prioritized over commercial interest, for instance. Research hypotheses, funding, experimental designs ought to be developed with a special consideration that they are meant to be primarily useful for the patient. Important steps are being taken in this direction. (more…)

Map versus terrain?

by Anna Luise Kirkengen

When discussing the potentials and limitations of “Evidence Based Medicine”, it might be reasonable to begin by examining the premises inherent in the concept. It might be wise to question, for example, whether the use of the word “Evidence” in this model represents an improper appropriation of the term, as if it had a single, specific meaning. One might object: “What is evident? Well, that depends.” (more…)